MedTrace Logo

Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)

NCT05566301 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1140

Last updated 2025-05-06

No results posted yet for this study

Summary

Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients to Clopidogrel undergoing carotid stenting and Clopidogrel in "responders" undergoing carotid stenting, in the onset of death and major adverse cardiovascular events (MACE) and bleeding events, 1 and 3 months after the procedure. Furthermore, the study aims to evaluate the possible preoperative clinical and pharmacological factors most associated with the phenomenon of resistance to Clopidogrel.

Inclusion criteria:

The data will be collected on adult patients (age\> 18 years) who have given their consent to participate in the study, belonging to the U.O. of Vascular Surgery of the IRCCS Policlinico San Donato and the U.O. of Vascular Surgery of the participating centers and there subjected to the treatment of carotid stenosis by stenting technique.

Exclusion criteria:

Those patients who are minors, who have not given their consent to participate in the study, or who have carotid stenosis not susceptible to intervention by stenting will be excluded from the study. Pregnant or lactating women will also be excluded from the study (such as situations in which carotid stenting is contraindicated regardless of the execution of the study).

Conditions

  • Clopidogrel, Poor Metabolism of
  • Carotid Stenosis

Interventions

DRUG

Clopidogrel

All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel

DRUG

Ticagrelor

All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel

Sponsors & Collaborators

  • IRCCS Policlinico S. Donato

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-02
Primary Completion
2026-09-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05566301 on ClinicalTrials.gov